About the Company
Develops supportive care products for cancer patients
Please visit http://www.tesarobio.com for more information about the company.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TSRO News
Dr. Marc Siegel Explains Why Tesaro (TSRO) Cancer Drug Is a Big Deal
In most cases ovarian cancer recurs within two years after chemotherapy, but the Tesaro (TSRO) drug stops that, Dr. Marc Siegel explained on Fox Business today. In most cases ovarian cancer recurs ...
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer
The RUBY Part 2 trial, sponsored by Tesaro Inc., a GSK group company, is a phase 3, randomized, double-blind, multicenter, placebo-controlled study. Eligible patients with primary advanced stage ...
An Executive Bought a Rival’s Stock. The SEC Says That’s Insider Trading.
SEC attorneys in 2020 questioned him about purchases of options tied to the shares of cancer-focused drugmakers Tesaro and Relypsa, according to court records. GlaxoSmithKline acquired Tesaro ...
GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro
GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug specialists Tesaro for around $5.1 billion. GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug ...
GSK application for expanded indication of Jemperli plus chemotherapy accepted by USFDA for priority review
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License ...
David M Mott's Net Worth
Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...
Radiotherapy-Induced Nausea and Vomiting Treatment Market Size, Share and Growth Opportunities
The Radiotherapy-Induced Nausea and Vomiting Treatment Market is undergoing significant transformations, influenced heavily by its interconnectedness with various end-use industries. These industries ...
NEW ENTERPRISE ASSOCIATES 13 LP's Net Worth
Who is NEW ENTERPRISE ASSOCIATES 13 LP? NEW ENTERPRISE ASSOCIATES 13 LP has an estimated net worth of $1.67 Billion. This is based on reported shares across multiple companies, which include ...
Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain ...
GSK : Jemperli Granted Priority Review By FDA For Expanded Use In Endometrial Cancer Treatment
The US Food and Drug Administration accepted the supplemental Biologics License Application or sBLA for Jemperli (dostarlimab) in combination with standard-of-care chemotherapy (carboplatin and ...
Netlist, Inc. (NLST)
Netlist, Inc. (PNK:NLST) Q1 2024 Earnings Call Transcript April 25, 2024 Netlist, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.05. NLST isn’t one of ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Loading the latest forecasts...